Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Detection of oral squamous cell carcinoma metastasis with cathepsin D: An immunohistochemical approach.

Dental research journal·2014

Same author

Association of Human Papilloma Virus 16 Infection and p53 Polymorphism among Tobacco using Oral Leukoplakia Patients: A Clinicopathologic and Genotypic Study.

International journal of preventive medicine·2014

Same author

A review of histopathological and immunohistochemical parameters in diagnosis of metastatic renal cell carcinoma with a case of gingival metastasis.

Journal of cancer research and therapeutics·2013

Same author

Statin Hepatotoxicity: Is it a Real Concern?

Heart views : the official journal of the Gulf Heart Association·2012

Same author

Iptakalim: A novel multi-utility potassium channel opener.

Journal of pharmacology & pharmacotherapeutics·2012

Same author

Blue cures blue but be cautious.

Journal of pharmacy & bioallied sciences·2012

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Newer antithrombotic drugs.

Pranav Sikka¹, V K Bindra

¹Department of Pharmacology, ITS-CDSR, Muradnagar, Ghaziabad, Uttar Pradesh, India.

Indian Journal of Critical Care Medicine : Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine

|May 17, 2011

Summary

This summary is machine-generated.

Developing safer and more effective antithrombotic drugs remains critical for treating thromboembolic disorders. Current treatments, while useful, highlight the ongoing need for improved medications to combat thrombosis and reduce mortality.

Keywords:

Antiplatelet drugs antithrombotic drugs thrombin inhibitors

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Related Experiment Videos

Last Updated: Jun 2, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Area of Science:

Pharmacology
Cardiovascular Medicine
Drug Discovery

Background:

Thromboembolic disorders pose a significant global health burden, causing substantial mortality and disability.
Existing antithrombotic therapies, including antiplatelets and anticoagulants, have limitations such as side effects and drug interactions.
Despite advancements, there is a continuous need for safer and more efficacious drugs to manage arterial and venous thrombosis.

Purpose of the Study:

To review the current landscape of antithrombotic drug development.
To highlight the limitations of existing treatments and the necessity for novel therapeutic agents.
To discuss the mechanisms and ongoing research in developing advanced antithrombotic medications.

Main Methods:

Literature review of existing and emerging antithrombotic drugs.
Analysis of drug classes, including antiplatelets (e.g., Aspirin, Clopidogrel, Prasugrel, Ticagrelor) and anticoagulants (e.g., Warfarin, direct thrombin inhibitors, Factor Xa inhibitors).
Discussion of drug mechanisms, clinical applications, and research trends in thromboembolic disorder management.

Main Results:

Aspirin, Clopidogrel, Ticlopidine, and GpIIb/IIIa inhibitors are established treatments.
Warfarin remains in use but faces challenges due to side effects and interactions.
Newer agents like Prasugrel, Ticagrelor, Cangrelor, Ximelgatran, Dabigatran, Apixaban, and Idrabiotaparinux represent advancements in antithrombotic therapy.

Conclusions:

The development of novel antithrombotic drugs is crucial for improving patient outcomes in thromboembolic disorders.
Ongoing research focuses on enhancing drug safety and efficacy by targeting specific steps in thrombus formation.
The field continues to evolve, with new direct oral anticoagulants and antiplatelet agents offering improved therapeutic options.